X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (176) 176
Publication (13) 13
Patent (5) 5
Report (2) 2
Book Chapter (1) 1
Dissertation (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (102) 102
male (75) 75
female (62) 62
middle aged (61) 61
aged (57) 57
risk factors (55) 55
mortality (46) 46
medicine, general & internal (38) 38
adult (34) 34
abridged index medicus (30) 30
cardiovascular disease (29) 29
prospective studies (25) 25
cholesterol (23) 23
internal medicine (22) 22
stroke (22) 22
urology & nephrology (22) 22
risk (21) 21
studies (21) 21
treatment outcome (21) 21
blood pressure (19) 19
cardiovascular-disease (19) 19
randomized controlled trials as topic (18) 18
aged, 80 and over (17) 17
clinical trials (17) 17
follow-up studies (17) 17
statins (17) 17
chronic kidney disease (16) 16
heart attacks (16) 16
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (16) 16
cardiac & cardiovascular systems (15) 15
chronic kidney-disease (15) 15
health risk assessment (15) 15
cancer (14) 14
medical and health sciences (14) 14
medical research (14) 14
medicin och hälsovetenskap (14) 14
research (14) 14
bias (13) 13
cardiovascular diseases - prevention & control (13) 13
cholesterol, ldl - blood (13) 13
drug therapy (13) 13
health aspects (13) 13
myocardial-infarction (13) 13
nephrology (13) 13
anticholesteremic agents - therapeutic use (12) 12
cardiovascular diseases (12) 12
coronary-heart-disease (12) 12
disease (12) 12
meta-analysis (12) 12
metaanalysis (12) 12
age (11) 11
clinical medicine (11) 11
glomerular filtration rate (11) 11
heart (11) 11
population (11) 11
prevention (11) 11
risk assessment (11) 11
risk-factors (11) 11
analysis (10) 10
cardiovascular diseases - mortality (10) 10
cohort studies (10) 10
disease progression (10) 10
epidemiology (10) 10
follow-up (10) 10
klinisk medicin (10) 10
primary prevention (10) 10
renal insufficiency, chronic - complications (10) 10
association (9) 9
cause of death (9) 9
diabetes (9) 9
outcomes (9) 9
prevalence (9) 9
prognosis (9) 9
public, environmental & occupational health (9) 9
time factors (9) 9
albuminuria (8) 8
c-reactive protein (8) 8
coronary heart disease (8) 8
original (8) 8
severity of illness index (8) 8
simvastatin - therapeutic use (8) 8
smoking - adverse effects (8) 8
age factors (7) 7
blood-pressure (7) 7
body mass index (7) 7
cardiovascular diseases - etiology (7) 7
care and treatment (7) 7
confidence intervals (7) 7
death (7) 7
disease prevention (7) 7
end-stage renal disease (7) 7
evidence-based medicine (7) 7
glomerular-filtration-rate (7) 7
hemodialysis (7) 7
hypertension (7) 7
incidence (7) 7
kidney diseases (7) 7
lipids (7) 7
placebo-controlled trial (7) 7
renal dialysis (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2011, Volume 377, Issue 9784, pp. 2181 - 2192
Summary Background Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary... 
Internal Medicine | UNITED-KINGDOM HEART | DESIGN | METAANALYSIS | REQUIRING PROLONGED OBSERVATION | EFFICACY | CARDIOVASCULAR EVENTS | SAFETY | HEMODIALYSIS | OUTCOMES | UMCG Approved | PARTICIPANTS | MEDICINE, GENERAL & INTERNAL | Confidence Intervals | Simvastatin - adverse effects | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Ezetimibe | Renal Dialysis - methods | Male | Reference Values | Cholesterol, LDL - analysis | Kidney Function Tests | Renal Insufficiency, Chronic - drug therapy | Dose-Response Relationship, Drug | Renal Insufficiency, Chronic - therapy | Renal Dialysis - mortality | Time Factors | Renal Insufficiency, Chronic - mortality | Adult | Female | Renal Insufficiency, Chronic - diagnosis | Drug Therapy, Combination | Severity of Illness Index | Hypolipidemic Agents - adverse effects | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Simvastatin - administration & dosage | Cholesterol, LDL - drug effects | Treatment Outcome | Azetidines - administration & dosage | Hypolipidemic Agents - administration & dosage | Survival Analysis | Aged | Simvastatin | Low density lipoproteins | Physiological aspects | Drug therapy, Combination | Research | Kidney diseases | Diagnosis | Drug therapy | Health aspects | Studies | Heart failure | Cardiac arrhythmia | Medical imaging | Hospitals | Compliance | Cardiovascular disease | Blood pressure | Family medical history | Cholesterol | Cancer | Mortality | myocardial infarction | cholesterol | councils | Dialysis | medical research | stroke | Kidney | Fast track
Journal Article
BMJ, ISSN 1756-1833, 2019, Volume 366, p. l4898
Assessment of risk of bias is regarded as an essential component of a systematic review on the effects of an intervention. The most commonly used tool for... 
CONSENSUS | MEDICINE, GENERAL & INTERNAL | QUALITY | TREAT | ASSESSMENTS | INTENTION | Research Design | Bias
Journal Article
by Storey, Benjamin C and Staplin, Natalie and Haynes, Richard and Reith, Christina and Emberson, Jonathan and Herrington, William G and Wheeler, David C and Walker, Robert and Fellström, Bengt and Wanner, Christoph and Landray, Martin J and Baigent, Colin and Storey, Benjamin C and Staplin, Natalie and Haynes, Richard and Reith, Christina and Emberson, Jonathan and Herrington, Will G and Wheeler, David C and Walker, Robert and Fellström, Bengt and Wanner, Christoph and Landray, Martin J and Baigent, Colin and Baigent, Colin and Landray, Martin J and Reith, Christina and Emberson, Jonathan and Wheeler, David C and Tomson, Charles and Wanner, Christoph and Krane, Vera and Cass, Alan and Craig, Jonathan and Neal, Bruce and Jiang, Lixin and Hooi, Lai Seong and Levin, Adeera and Agodoa, Lawrence and Gaziano, Mike and Kasiske, Bertram and Walker, Robert and Massy, Ziad A and Feldt-Rasmussen, Bo and Krairittichai, Udom and Ophascharoensuk, Vuddidhej and Fellström, Bengt and Holdaas, Hallvard and Tesar, Vladimir and Wiecek, Andrzej and Grobbee, Diederick and de Zeeuw, Dick and Grönhagen-Riska, Carola and Dasgupta, Tanaji and Lewis, David and Herrington, William and Mafham, Marion and Majoni, William and Wallendszus, Karl and Grimm, Richard and Pedersen, Terje and Tobert, Jonathan and Armitage, Jane and Baxter, Alex and Bray, Christopher and Chen, Yiping and Chen, Zhengming and Hill, Michael and Knott, Carol and Parish, Sarah and Simpson, David and Sleight, Peter and Young, Alan and Collins, Rory and The SHARP Collaborative Group and SHARP Collaborative Grp and SHARP Collaborative Group
Kidney International, ISSN 0085-2538, 04/2018, Volume 93, Issue 4, pp. 1000 - 1007
Markers of inflammation, including plasma C-reactive protein (CRP), are associated with an increased risk of cardiovascular disease, and it has been suggested... 
randomized trials | C-reactive protein | vascular disease | LDL cholesterol | inflammation | MORTALITY | EVENTS | METAANALYSIS | DIALYSIS PATIENTS | RENAL PROTECTION | HEMODIALYSIS-PATIENTS | UROLOGY & NEPHROLOGY | OUTCOMES | CORONARY-HEART-DISEASE | ASSOCIATION | Dyslipidemias - mortality | Dyslipidemias - complications | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Renal Insufficiency, Chronic - complications | Inflammation - blood | Inflammation - complications | Renal Insufficiency, Chronic - therapy | Dyslipidemias - blood | C-Reactive Protein - metabolism | Time Factors | Cardiovascular Diseases - mortality | Renal Insufficiency, Chronic - mortality | Cholesterol, LDL - blood | Female | Inflammation - mortality | Severity of Illness Index | Cardiovascular Diseases - etiology | Dyslipidemias - drug therapy | Down-Regulation | Risk Factors | Inflammation Mediators - blood | Treatment Outcome | Ezetimibe, Simvastatin Drug Combination - adverse effects | Biomarkers - blood | Ezetimibe, Simvastatin Drug Combination - therapeutic use | Anticholesteremic Agents - adverse effects | Randomized Controlled Trials as Topic | Renal Insufficiency, Chronic - blood | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Aged | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Kidneys | Hemodialysis | Simvastatin | Cardiovascular disease | Inflammation | Apolipoproteins | Low density lipoprotein | Cholesterol | Studies | Proteins | Body mass index | Arteriosclerosis | Blood pressure | Cardiovascular diseases | Health risk assessment | Heart diseases | Statins
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 388, Issue 10059, pp. 2532 - 2561
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 384, Issue 9958, pp. 1929 - 1935
Journal Article